| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 18971495150; |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:PF-05231023
CAS:1037589-69-7
Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 18149758185; |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:PF-05231023
CAS:1037589-69-7
Purity:98% Package:10mg;100mg;1g;10g;100g;1kg
|
PF-05231023 manufacturers
|
| | PF-05231023 Basic information |
| Product Name: | PF-05231023 | | Synonyms: | PF-05231023;PF 5231023;PF-05231023; PF05231023; PF 05231023; PF-5231023; PF5231023; PF 5231023;PF5231023;PF-5231023;1H-Pyrrole-1-propanamide, 2,5-dihydro-2,5-dioxo-N-[2-[2-[3-oxo-3-[[4-[3-oxo-3-(2-oxo-1-azetidinyl)propyl]phenyl]amino]propoxy]ethoxy]ethyl]-;Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD;Mal-amido-PEG-2-C2-amido-Ph-C2-CO-AZD,PROTAC Linkers,MalamidoPEG2C2amidoPhC2COAZD,Inhibitor,Mal amido PEG2 C2 amido Ph C2 CO AZD,inhibit | | CAS: | 1037589-69-7 | | MF: | C26H32N4O8 | | MW: | 528.55 | | EINECS: | | | Product Categories: | | | Mol File: | 1037589-69-7.mol |  |
| | PF-05231023 Chemical Properties |
| Boiling point | 849.9±65.0 °C(Predicted) | | density | 1.345±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:4): 0.2 mg/ml | | form | A solid | | pka | 14.34±0.70(Predicted) | | color | White to off-white |
| | PF-05231023 Usage And Synthesis |
| Uses | Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (Mal-PEG2-AZD) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | | in vivo | | Animal Model: | Eight week old Zucker rats[3] | | Dosage: | 3mg/kg and 10mg/kg | | Administration: | Subcutaneously twice a week for two weeks | | Result: | There was no change of BW observed, and food intake was not changed in the treated groups compared to control. Caused a significant decrease of glucose excursion during the oral glucose tolerance test (OGTT) compared to control. |
| Animal Model: | 7-to-8-month-old Akita mice with type 1 diabete model[4] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneally injected; twice a week; for four weeks | | Result: | Administration improved retinal function in diabetic Akita mice. |
| | IC 50 | PEGs | | References | [1] Sonoda J, et al. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig. 2017 May 19;30(2). DOI:10.1515/hmbci-2017-0002 |
| | PF-05231023 Preparation Products And Raw materials |
|